Morgan Stanley Reiterates Equal-Weight on Alnylam Pharmaceuticals, Maintains $210 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has reiterated an Equal-Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $210 price target.
August 04, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Alnylam Pharmaceuticals and maintained a $210 price target.
The news is directly about Alnylam Pharmaceuticals and is likely to influence investor sentiment. However, as the rating and price target have been maintained, the immediate impact on the stock price may be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100